Alpha memo: resveratrol endurance exercise cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Recharacterize Receipt 1 honestly: it is a conference proceedings entry that describes study design/methods and does not report outcome data, so it cannot serve as evidence of translational failure. Either replace it with a full primary human trial with reported inflammatory or endurance outcomes, or reframe the memo's claim as 'preclinical positive signal with no decisive human receipt' rather than 'preclinical positive vs human negative.'
2. If a translational-contradiction framing is retained, add at least one additional source (e.g., a completed RCT of resveratrol + exercise in aged or trained adults reporting endurance or inflammatory endpoints) so the cross-context claim rests on more than one underpowered/design-only human receipt.
3. Clarify in the caveats that the 2011 receipt is a proceedings abstract and explicitly note that the human side of the comparison is currently evidence-vacuous, not evidence-negative.

Major issues

• Receipt 1 (2011 eccentric-exercise inflammatory markers trial) appears to be a conference abstract/proceedings entry (J Int Soc Sports Nutr 2011, 8(Suppl 1):P15), not a full primary research report; the abstract excerpt frames the study as design/protocol and does not report favorable inflammatory results. The memo states the abstract 'reports the design but not a confirmed favorable shift in these endpoints' — this means the human receipt does not actually demonstrate a translational failure, it merely lacks a result. The 'not translate cleanly' claim is therefore weakly supported because the null/negative evidence is an absence rather than a demonstrated negative finding.
• The cross-context signal hinges on a cross-species, cross-dose, cross-modality, cross-endpoint comparison that the memo itself acknowledges is heavily confounded. With only one preclinical positive receipt and one human pilot with no reported result, the 'heterogeneous cross-context signal' framing overstates what two receipts — one of which is design-only — can establish.

Minor issues

• The abstract excerpt for Receipt 1 cuts off mid-sentence and does not report any results, yet the memo uses this receipt as evidence of translational non-cleanliness. Consider explicitly noting that this is a proceedings abstract with no reported outcome data.
• The memo does not cite a third bridging or confirmatory source to triangulate either the preclinical or human side; a third independent aged-mice endurance study or a larger human endurance trial would strengthen the signal.
• Title says 'cross-context evidence signal' which is acceptable, but the lede slightly implies a translational contradiction that Receipt 1 does not actually support (no negative result reported).

Reviewer note

The memo is structurally clean and the source bundle is verifiable, recent, and aligned with the title (resveratrol + exercise, endurance context). Receipt 2 directly supports the preclinical claim, and Receipt 1 is title-aligned with the human side. However, Receipt 1 is a conference proceedings abstract whose excerpt describes methods only and reports no outcomes; the memo acknowledges this but still uses it as the human anchor for a 'not translate cleanly' claim, which is a mild overclaim. The 'heterogeneous cross-context signal' framing requires either a true negative human result or a third bridging source. With bounded edits — either replacing Receipt 1 with a completed trial or honestly reframing the human side as evidence-vacuous — this is salvageable.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis